

10/594419

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IAPO1 Rec'd PCT/PTO 26 SEP 2006

In re Application of
THEIS et al.

Examiner: **Unknown**

Art Unit: **Unknown**

Application No.: **To Be Assigned**

Filed: **Herewith**

Title: **Dual-transfected Cells Lines As In Vitro
Screening Tools For Pharmaceutical Compound
Profiling: A Model For Hepatobiliary Elimination**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, on

Date of Deposit

Sept. 26, 2006

Signature

Debra Coughlin

EL964833681US


Express Mail No.

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,


Ann Marie Szczepanik, Reg. No. 52,267
Agent for Applicant

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4757
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2004/0025 US PCT